HMX2 and fatty liver disease: A total of 38.7% male gMX2 + Dox and 53.3% male hMX2 + Dox fish had advanced HCC with control treatment, only 23.1% gMX2 + Dox and 30.3% hMX2 + Dox males had clear HCC with E2 treatment, the dramatic growth of HCC population in gMX2 + Dox (71.2%) and hMX2 + Dox (86.4%) after 11-KT treatment, and the rest had fatty liver disease (FLD) compared with MXs−Dox fish (Figure 8C).